News
DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS SIGN LICENSING DEAL FOR A BIOSIMILAR ASSET
DGAP-News: JUST - EVOTEC BIOLOGICS & BIOCON BIOLOGICS UNTERZEICHNEN LIZENZVEREINBARUNG FÜR EIN BIOSIMILAR-PROGRAMM
DGAP-News: Gerresheimer AG: Gerresheimer treibt Wachstums- und Technologieprojekte im dritten Quartal voran
DGAP-News: Gerresheimer AG: Gerresheimer advances growth and technology projects in third quarter
DGAP-News: EVOTEC UND CELMATIX GEHEN STRATEGISCHE ZUSAMMENARBEIT EIN
DGAP-News: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition
DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt CEO Führungswechsel bekannt
DGAP-Adhoc: QIAGEN N.V.: QIAGEN gibt Abweichung von den vorläufigen Umsatzzahlen für das dritte Quartal 2019 bekannt
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio
The Billion-Dollar Augmented Reality Battle Has Begun
Meta Platforms (NASDAQ: META) wowed the market with the unveiling of the Orion augmented reality (AR) glasses last week, but they won't go on sale for years. Meanwhile, Snap (NYSE: SNAP) showed off
EQS-Adhoc: Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025
Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries
EQS-News: Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
Neuen Daten zufolge bewirkt EBGLYSS® (Lebrikizumab) von Almirall eine nachhaltige Linderung bei mehr als 80 % der Erwachsenen und Jugendlichen mit mittelschwerer bis schwerer atopischer Dermatitis nach einer Behandlung von bis zu 3 Jahren
Bei mehr als 80 Prozent der Erwachsenen und Jugendlichen mit mittelschwerer bis schwerer atopischer Dermatitis, die in den Monotherapie-Studien ADvocate 1 und 2 in Woche 16 auf die Behandlung mit
Why Masimo Stock Crushed the Market Today
Medical tech company Masimo (NASDAQ: MASI) had some significant C-suite news to report on Wednesday, and investors clearly welcomed this. They collectively pushed the company's stock up by 6% across
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued
EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
Why Tandem Diabetes Care Stock Thrashed the Market Today
Tandem Diabetes Care (NASDAQ: TNDM) had some encouraging news to report on the regulatory front Thursday, and after it hit the headlines investors piled into the stock. At the end of the day the
Why Penumbra Stock Zoomed Nearly 5% Higher Today
Veteran medical device maker Penumbra (NYSE: PEN) got a shot of good news on Wednesday. An analyst initiated coverage of the company's stock with a rather bullish review, and investors took this to
EQS-News: Gerresheimer: EcoVadis Gold with further improved score
Novocure Announces Planned CEO Transition
Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed